
    
      This trial will be the first clinical study in humans with the product, which until then has
      been studied only in experimental models. Given the current epidemiological impact of cancer
      and the need to improve its systemic treatment, making it available to a larger portion of
      the Brazilian population, it is proposed to conduct the first Amblyomin-X study in cancer
      patients, more specifically those with advanced solid tumors For which there is no
      contraindicated or inaccessible therapeutic option established as the standard at the time of
      inclusion in the study.
    
  